No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
DIVA Laboratories, Ltd. specializes in the global provision of advanced display technologies. Its comprehensive product lineup caters to critical environments, including specialized endo/surgical displays designed to render both static and dynamic imagery with precision for hybrid and integrated operating theaters, as well as crucial control room applications. Furthermore, DIVA offers a range of color and monochrome monitors tailored for high-accuracy radiology and broader medical imaging purposes. Beyond healthcare, the company develops interactive touch displays and human-machine interface (HMI) solutions, alongside robust medical and industrial enclosures. DIVA also serves original design manufacturers (ODMs) and original equipment manufacturers (OEMs) with custom display units, in addition to a broader portfolio of video solutions. Established in 1995, DIVA Laboratories, Ltd. maintains its corporate headquarters in New Taipei City, Taiwan.
www.diva.com.twNo one on the platform currently holds 4153.TWO.
No tracked institution reports a position in 4153.TWO as of their last filing.
No one on the platform has traded 4153.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 15.8% | 13.3% | — | — | — | |
| Rev. Growth % | 0.8% | 3.3% | ||||
| Profit Margin % | 10.4% | 7.6% | ||||
| Free Cash Flow Margin % | 2.3% | 9.4% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.2B | +17.2% | $2.03 | $2.03–$2.03 | — | 1 |
| 2027 | $740M | -37.1% | $1.13 | $1.13–$1.13 | — | 1 |
| 2028 | $740M | +0.0% | $1.13 | $1.13–$1.13 | — | 1 |
| 2029 | $900M | +21.6% | $1.60 | $1.60–$1.60 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $39.45 |
| -0.38% |
| $1.8B |
| — |
| 6527.TWOCrystalvue Medical Corporation | $75.20 | +0.27% | $1.9B | — |
| 6637.TWOMedical Imaging Corporation | $54.00 | +0.00% | $1.4B | — |
Source: Financial Modeling Prep · peers by sector/industry